Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
NCT02512926
Age 6 - 29
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
Doctors want to see if a medicine called carfilzomib can help children with cancer. They will give carfilzomib with two other medicines, cyclophosphamide and etoposide, which are already used to treat cancer in children. This study will help doctors figure out the right dose of carfilzomib to give to children with leukemia or solid tumors. Carfilzomib is approved for adults with a type of cancer, but not for children.
Doctors want to see if a medicine called carfilzomib can help children with cancer. They will give carfilzomib with two other medicines, cyclophosphamide and etoposide, which are already used to treat cancer in children. This study will help doctors figure out the right dose of carfilzomib to give to children with leukemia or solid tumors. Carfilzomib is approved for adults with a type of cancer, but not for children.
Third Opinion AI Generated Synopsis
Trial Summary
This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia. The medications cyclophosphamide and etoposide are standard drugs often used together for the treatment of cancer in children with solid tumors or leukemia. Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults with multiple myeloma (a type of cancer). However, this drug is not approved to treat children with relapsed/refractory solid tumors or leukemia. With this research, we plan to determine the DLTs and MTD of Carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors.
This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia. The medications cyclophosphamide and etoposide are standard drugs often used together for the treatment of cancer in children with solid tumors or leukemia. Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults with multiple myeloma (a type of cancer). However, this drug is not approved to treat children with relapsed/refractory solid tumors or leukemia. With this research, we plan to determine the DLTs and MTD of Carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
